Androgen deprivation therapy affects BCL-2 expression in human prostate cancer
Open Access
- 22 July 2011
- journal article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 39 (5) , 1233-1242
Abstract
BCL-2 is an integral protein of the external mitochondrial membrane that inhibits cell apoptotic death. We investigated the effect of androgen deprivation therapy (ADT) on BCL-2 expression in prostate cancer tissues. We studied BCL-2 expression in vivo in prostate cancer tissues obtained from patients who underwent radical prostatectomy after neoadjuvant ADT, by Northern and Western blot analysis, and immunohistochemistry. Moreover, gene transcriptional activity was also measured by nuclear run-on experiments. We demonstrated an increase of BCL-2 mRNA expression in patients who underwent neoadjuvant ADT for 1 month in comparison to patients who had not received any therapy. Moreover, we demonstrated that there were no significant modifications of BCL-2 mRNA levels in patients who underwent neoadjuvant ADT for 3 and 6 months. Furthermore, BCL-2 protein levels in patients who underwent neoadjuvant ADT for 1 month were upregulated in comparison to patients who had not received any therapy. Immunohistochemical analysis showed a strong positivity of prostate cells depending on ADT administration for 1 month. Finally, transcriptional activity was not modified in patients who underwent neoadjuvant ADT, suggesting the absence of hormonal regulation on BCL-2 gene expression at the transcriptional level. Our data show that short-term administration of ADT interferes with BCL-2 expression, suggesting that androgen-mediated mechanisms may act through BCL-2-mediated apoptotic pathways. Moreover, since short-term ADT administration does not interfere with BCL-2 expression at the transcriptional level, the androgen-mediated mechanisms involving BCL-2 pathways, probably act at the post-transcriptional level.Keywords
This publication has 23 references indexed in Scilit:
- Truncated Bcl-2, a potential pre-metastatic marker in prostate cancerBiochemical and Biophysical Research Communications, 2003
- Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003
- Molecular markers of outcome after radiotherapy in patients with prostate carcinomaCancer, 2003
- Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independentBiochemical Pharmacology, 2002
- The development of androgen-independent prostate cancerNature Reviews Cancer, 2001
- APOPTOSIS AND BCL-2 EXPRESSION IN PROSTATE CANCER: SIGNIFICANCE IN CLINICAL OUTCOME AFTER BRACHYTHERAPYJournal of Urology, 2001
- Regulation of mRNA and Protein Levels of β1 Integrin Variants in Human Prostate CarcinomaThe American Journal of Pathology, 2000
- Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotidesUrology, 1999
- Comparison of Glyceraldehyde-3-phosphate Dehydrogenase and 28S-Ribosomal RNA Gene Expression as RNA Loading Controls for Northern Blot Analysis of Cell Lines of Varying Malignant PotentialAnalytical Biochemistry, 1994
- Histologic grading of prostate cancer: A perspectiveHuman Pathology, 1992